Drug Trial Radar · NCT03235544
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
162
Actual
Start
Nov 20, 2017
Primary completion
Apr 30, 2024
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Aug 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.
Conditions
- Lymphoma
Interventions
ParsaclisibDrug
Parsaclisib tablets administered orally with water and without regard to food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 1016 days
Locations
103 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Comprehensive Cancer Center
Birmingham, Alabama
St. Joseph Heritage Healthcare
Santa Rosa, California
Rocky Mountain Cancer Center-Aurora
Aurora, Colorado
Asclepes Research Centers
Brooksville, Florida
Moffitt Cancer Center
Tampa, Florida
Bond & Steele Clinic, P.A.
Winter Haven, Florida
Rush University Medical Center
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
Illinois Cancer Specialists
Niles, Illinois
Hattiesburg Clinic Hematology
Hattiesburg, Mississippi
Clinical Research Alliance, Inc.
New Hyde Park, New York
Duke University Medical Center
Durham, North Carolina
Oncology Hematology Care, Inc.
Cincinnati, Ohio
Willamette Valley Cancer Institute
Eugene, Oregon
Kaiser Permanente - Northwest
Portland, Oregon
Gettysburg Cancer Center
Gettysburg, Pennsylvania
Texas Oncology
Austin, Texas
Texas Oncology San Antonio
San Antonio, Texas
Renovatio Clinical
The Woodlands, Texas
Texas Oncology - Tyler
Tyler, Texas
Yakima Valley Memorial Hospital/North Star
Yakima, Washington
Institut Jules Bordet
Brussels, Belgium
Hopital de Jolimont
La Louvière, Belgium
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, Belgium
Universitair Ziekenhuis Gent
Ghent, Oost-Vlaanderen, Belgium
Fakultni Nemocnice Hradec Kralove
Hradec Králové, Czechia
Fakultni Nemocnice Kralovske Vinohadry, Interni Hematologicka Klinika
Prague, Czechia
Charles University General Hospital
Prague, Czechia
Fakultni Nemocnice Kralovske Vinohrady
Prague, Czechia
Aalborg University Hospital
Aalborg, Denmark
Aarhus Universitets Hospital
Aarhus, Denmark
Odense Universitetshospital (Ouh) (Odense University Hospital)
Odense C, Denmark
Zealand University Hospital
Roskilde, Denmark
Avicenne Hospital
Bobigny, France
Chu de Clermont - Ferrand- Hospital Estaing
Clermont-Ferrand, France
Centre Hospitalier Universitaire Henri Mondor
Créteil, France
University Hospital Grenoble
Grenoble, France
Centre Hospitalier Departemental - La-Roche-Sur-Yon - Les Oudairies
La Roche-sur-Yon, France
Centre Hospitalier Universitaire de Grenoble
La Tronche, France
Centre Hospitalier de Versailles
Le Chesnay, France
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.